
Biotech Maxion Therapeutics scores £58m round to tackle inflammatory disease
Maxion Therapeutics, a Cambridge biotech firm developing treatments for inflammatory diseases, has closed a £58m Series A round. The company is developing antibody-based drugs called KnotBodies, which are designed to overcome the challenges of targeting …